Overview

The Effects of RPL554 on Top of Standard COPD Reliever Medications

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a randomised sequence: 1. salbutamol, 2. ipratropium, 3. salbutamol + RPL554, 4. ipratropium + RPL554, 5. RPL554 6. Placebo
Phase:
Phase 2
Details
Lead Sponsor:
Verona Pharma plc
Treatments:
Albuterol
Ipratropium